At the news
? NEUTRALIMPACT 6/10 S-4 filed Aug 24, 2026 at 21:50 ET
Repligen filed an S-4 registration statement for its acquisition of BioLife Solutions (BLFS). BioLife stockholders will receive $11.25 cash and 0.1442 Repligen shares per BLFS share, implying a value of ~$37.37 based on RGEN's August 21 close. The deal is expected to close in Q4 2026, subject to BioLife stockholder approval, HSR clearance, and other conditions. The fixed exchange ratio means the stock consideration value fluctuates with RGEN's price, creating uncertainty for BLFS holders voting on the deal.
- Repligen is acquiring BioLife Solutions via a two-step merger for $11.25 cash + 0.1442 RGEN shares per BLFS share.
- The implied value per BLFS share was ~$37.37 as of August 21, 2026, based on RGEN's $181.13 close.
- BioLife stockholders must approve the merger; a special meeting is scheduled for [], 2026.
- The deal is expected to close in Q4 2026, subject to HSR clearance and other conditions.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access